All Ankura Insights

8/27/2025 2:03:20 PM

Purchase Price Allocations of Life Sciences Companies

By Sara Jane Askew Richard Hitt CJ DeKreek

Ankura is pleased to present the findings of our analysis of the allocation of the purchase price for transactions involving...

8/25/2025 12:00:19 PM

Most Favored Nation Drug Pricing Developments

By Jeffrey Low Jed Smith Katherine Norris +1 more...

On July 31, 2025, the White House released a fact sheet[1] discussing additional steps taken by the Trump administration surrounding...

5/23/2025 7:12:03 PM

Most-Favored-Nation, Executive Order 14297|Forward Looking Perspectives for Drug Manufacturers, Pharmacy Benefit Managers, Health Plans, and Pharmacies

By Jeffrey Low Jed Smith Katherine Norris

On May 12, 2025, U.S. President Donald Trump signed an executive order (EO) titled “Delivering Most-Favored-Nation Prescription Drug...

4/22/2025 5:24:48 PM

GLP-1 Drugs: Catalysts for a Healthier Lifestyle and a Revolution in Consumer Spending

By Chris Ventry Keith Jelinek Rick Maicki

As increased usage of Glucagon-like peptide medications, or “GLP-1s,” sweeps the country and reshapes consumer behavior, a noticeable...

1/31/2025 7:02:06 PM

HIPAA Security Risk Analysis – How should regulated entities prepare for the Office for Civil Rights (OCR) Risk Analysis Audit Initiative

By Matt Flora

Following the Office for Civil Rights (OCR) recent publication of four settlements as part of a new Risk Analysis Audit Initiative. We...

7/17/2024 8:50:56 PM

FDA Will Now Regulate Laboratory Developed Tests

By Darri Scalzo

On April 29, 2024, the Food and Drug Administration (FDA) announced a final rule to consider laboratory-developed tests (LDTs) to be...

3/15/2024 1:42:23 PM

Recent Research Misconduct Concerns Warrant More Effective Diligence: Using AI Tools To Improve Research Integrity Processes

By Darri Scalzo

In just the first few weeks of 2024, two separate cases of allegations of research misconduct have been publicized. In both cases, the...

3/11/2024 1:00:21 PM

The Focus of Federal Proposals on Pharmacy Benefit Management – 118th Congress

By Jeffrey Low

Featured Excerpt Over the past several years, legislators nationwide have scrutinized Pharmacy Benefit Managers (PBMs) due to various...

4/5/2021 4:17:14 PM

Changes to Part D Formulary Flexibilities under Biden Administration

By Dorothy DeAngelis

It is inevitable that the Biden administration would review and make changes to the Part D drug pricing agenda set forth by the Trump...

Social Media Links

Purchase Price Allocations of Life Sciences Companies

Most Favored Nation Drug Pricing Developments

Most-Favored-Nation, Executive Order 14297|Forward Looking Perspectives for Drug Manufacturers, Pharmacy Benefit Managers, Health Plans, and Pharmacies

GLP-1 Drugs: Catalysts for a Healthier Lifestyle and a Revolution in Consumer Spending

HIPAA Security Risk Analysis – How should regulated entities prepare for the Office for Civil Rights (OCR) Risk Analysis Audit Initiative

FDA Will Now Regulate Laboratory Developed Tests

Recent Research Misconduct Concerns Warrant More Effective Diligence: Using AI Tools To Improve Research Integrity Processes

The Focus of Federal Proposals on Pharmacy Benefit Management – 118th Congress

Changes to Part D Formulary Flexibilities under Biden Administration

Let’s Connect

Follow

Explore

Learn